Literature DB >> 21610679

Diabetes: ROADMAP: the road to renoprotection?

Sara S Roscioni, Hiddo J Lambers Heerspink, Dick de Zeeuw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21610679     DOI： 10.1038/nrneph.2011.71

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial.

Authors:  Yan Miao; Stefan A Ottenbros; Goos D Laverman; Barry M Brenner; Mark E Cooper; Hans-Henrik Parving; Diederick E Grobbee; Shahnaz Shahinfar; Dick de Zeeuw; Hiddo J Lambers Heerspink
Journal:  Hypertension       Date:  2011-05-31       Impact factor: 10.190

Review 2.  The kidney, a cardiovascular risk marker, and a new target for therapy.

Authors:  Dick de Zeeuw; Hans L Hillege; Paul E de Jong
Journal:  Kidney Int Suppl       Date:  2005-09       Impact factor: 10.545

3.  ONTARGET still OFF-TARGET?

Authors:  Hiddo J Lambers Heerspink; Dick de Zeeuw
Journal:  Circulation       Date:  2011-02-28       Impact factor: 29.690

Review 4.  Telmisartan: a different angiotensin II receptor blocker protecting a different population?

Authors:  M Burnier
Journal:  J Int Med Res       Date:  2009 Nov-Dec       Impact factor: 1.671

5.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

6.  Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

Authors:  Hermann Haller; Sadayoshi Ito; Joseph L Izzo; Andrzej Januszewicz; Shigehiro Katayama; Jan Menne; Albert Mimran; Ton J Rabelink; Eberhard Ritz; Luis M Ruilope; Lars C Rump; Giancarlo Viberti
Journal:  N Engl J Med       Date:  2011-03-10       Impact factor: 91.245

7.  Preventing microalbuminuria in type 2 diabetes.

Authors:  Piero Ruggenenti; Anna Fassi; Anelja Parvanova Ilieva; Simona Bruno; Ilian Petrov Iliev; Varusca Brusegan; Nadia Rubis; Giulia Gherardi; Federica Arnoldi; Maria Ganeva; Bogdan Ene-Iordache; Flavio Gaspari; Annalisa Perna; Antonio Bossi; Roberto Trevisan; Alessandro R Dodesini; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2004-10-31       Impact factor: 91.245

8.  Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.

Authors:  Tazeen H Jafar; Paul C Stark; Christopher H Schmid; Marcia Landa; Giuseppe Maschio; Paul E de Jong; Dick de Zeeuw; Shahnaz Shahinfar; Robert Toto; Andrew S Levey
Journal:  Ann Intern Med       Date:  2003-08-19       Impact factor: 25.391

Review 9.  Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most.

Authors:  Folkert W Asselbergs; Wiek H van Gilst
Journal:  Curr Opin Cardiol       Date:  2007-07       Impact factor: 2.161

10.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.